46 Major Salivary Gland Tumours • Pleomorphic adenoma—most common in parotid, 1% risk of malignant change per year after 10 years • Warthin (papillary cystadenoma lymphomatosum)—smoking risk factor, 10% bilateral, M:F 5:1 • Monomorphic adenoma—most common is basal cell adenoma • Oncocytomas—more common in elderly • 80% benign • Most common pleomorphic adenoma • Investigations – Pros—preop planning and patient counselling – Cons—most likely treatment is surgical so result does not change plans – Pros—deep lobe component can be identified, good for preop planning and counseling; lymph nodes not detected clinically may be identified therefore affecting treatment plan; infiltrative margins may raise possibility of malignancy – Cons—if no nodes palpable, unlikely to change treatment • 50% benign • Investigations – Pros—treatment planning – Cons—management of non-diagnostic samples; some laboratories require larger cellular volumes to diagnose lymphomas • 25% benign • Can occur within sinuses, nasal cavity, and larynx • Investigations • Epidemiology • Presentation • Mucoepidermoid carcinoma—most common malignant tumour, graded: low, medium, high • Adenoid cystic carcinoma—most common submandibular gland malignancy, increased risk perineural invasion, lung metastases more common than nodal • Acinic cell carcinoma—low-grade neoplasm, late recurrences even after 30 years • Adenocarcinoma—classified into low- and high-grade types • Squamous cell carcinoma—consider lymph node metastases from melanoma, skin • Carcinoma ex-pleomorphic adenoma—longstanding history of parotid swelling with rapid increase in size, aggressive, 5-year survival 40% • Salivary duct carcinoma—poor prognosis, 50% present with nodal metastases • Lymphoma—may require trucut biopsy to diagnose • See Table 46.1 • T1—≤2 cm • T2—2 to 4 cm • T3—extraparenchymal extension without VII n involvement and <6 cm • T4—invades skull base, VII n and/or >6 cm • Poorly differentiated carcinoma—23 to 26% • Adenoid cystic carcinoma—23 to 26% • Carcinoma ex-pleomorphic adenoma—9 to 14% • Acinic cell carcinoma 3% • Most common is surgery ± postoperative radiotherapy (PORT) • Operations include: – ± Excision skin with free flap or keystone repair – ± Neck dissection – ± Pinnectomy – ± Petrosectomy – ± Temporomandibular joint excision • Most common is surgery ± PORT • Dependent on site of tumour may require jaw split
46.1 Benign Tumours
46.2 Parotid Tumours
Fine needle aspiration (FNA) ± US guided
CT/MRI
46.3 Submandibular Tumours
FNA ± US guided
46.4 Minor Salivary Gland Tumours
Biopsy under local anaesthetic or general anaesthetic
CT/MRI to evaluate the extent of tumour and nodal status
46.5 General Notes on Salivary Gland Malignancy
1 to 2/100,000
3 to 4% total head and neck malignancy
25% parotid, 50% SM glands, 75% minor salivary glands
Risk factors include: RT exposure and occupational silica dust (blast furnaces, cement, glass, ceramic, and clay industries) and nitrosamine (rubber and tire industries)
Mucoepidermoid most common (inc. children)
In children 65% tumours are benign, with haemangiomas being the most common
Typically painless neck swelling
CN VII n weakness indicative of malignancy
Malignancy normally >6th decade
Benign tumours normally >4th decade
46.6 Malignant Tumours
46.6.1 Staging of Salivary Gland Malignancies
46.6.2 Presentation of Facial Nerve Paralysis in Malignant Tumours
46.6.3 Treatment for Parotid Malignancy
Superficial parotidectomy + VII n preservation
Total parotidectomy ± excision of VII n + grafting
46.6.4 Treatment for Submandibular Malignancy
Submandibular gland excision ± neck dissection
46.6.5 Treatment for Minor Salivary Gland Malignancy
< div class='tao-gold-member'>
Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

